Roche partners with Zealand Pharma to advance petrelintide in obesity treatment
Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to develop and commercialise petrelintide obesity treatment, a promising amylin analog therapy ... Read More
AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra
AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company specializing in peptide-based drug discovery. The deal ... Read More